



**1537 NW 65<sup>th</sup> Avenue ♦ Plantation, Florida 33313**  
**Office (954) 509-0911 ♦ Fax (877) 895-5647**

January 12, 2021

Dear Fellow Shareholders of Nutra Pharma:

As we have persevered through 2020 and look forward to a much brighter 2021, I wanted to take this opportunity to update you on the current status of the Company, provide a review of 2020 and briefly outline our goals and expectations for the coming months.

Nutra Pharma Corporation operates as a biotechnology company specializing in products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brands Nyloxin<sup>®</sup>, Equine Pain-Away and Pet Pain-Away.

Even through the crises of 2020, we accomplished the following throughout the year:

- We announced that Dr. Dale VanderPutten, our CSO, presented a Tech Watch talk to an audience of military and civilian experts in chem/bio defense by invitation of the Defense Threat Reduction Agency ([DTRA](#)). He presented our nerve agent countermeasure technology in a talk titled "A Nicotinic Acetylcholine Receptor (nAChR) Directed Organophosphate Countermeasure".
- We greatly improved our online presence for our Nyloxin product line and created an Amazon storefront at [www.Amazon.com/Nyloxin](http://www.Amazon.com/Nyloxin) that contains in-depth product information as well as comparisons to other OTC pain products.
- We started selling Nyloxin for Chronic Pain Relief through the Walmart Marketplace at [www.Walmart.com](http://www.Walmart.com).
- We closed our Coral Springs offices to consolidate our operations at our Plantation, Florida laboratory and warehouse space. This streamlined operations in addition to cost savings of over \$100,000 annually.
- We eliminated all institutional debt with the company when a long-term investor purchased the last of these notes. We feel that this will be significantly healthier for the Company and our shareholders. This will allow us to move our business plan forward without fear of constant selling pressure from toxic convertible debt.
- We moved manufacturing in-house to allow for greater quality control and reduced lead times for product runs. This also provides a significant cost savings in production.
- We announced our dedication to transparency by re-engaging our Auditors and accountants to start filing our delinquent quarterly and annual reports. We have not filed these since the third quarter of 2018 and are working diligently to complete the process with the plan to be current in the first quarter of 2021.

Throughout 2021, we expect to continue actively marketing Nyloxin<sup>®</sup>, Pet Pain-Away and Equine Pain-Away. We are currently working to begin a broad retail rollout that follows our acceptance at Walmart.com. These sales will bring in the revenue that will bring the company to profitability as well as provide the financing for the proposed clinical studies.

In 2021, we plan to begin working with joint venture partners to begin clinical trials with our Multiple Sclerosis (MS) drug, RPI-78M under our Orphan designation for pediatric MS. The Orphan status of the drug will allow for faster, less expensive trials as we lay the groundwork for the eventual drug production and trial protocol development. It is our goal to complete the Phase I/II trials in pediatric MS over the next 18-24 months and then either move into Phase III trials or seek a licensing partner.

We also plan to move forward with our work in nerve agent counter-measures and are filing for several grants with US governmental agencies to fund that work.

We believe that we have set the path for a bright future starting with 2021. Sales growth and marketing expansion will allow for a better market for our products and services. Marketing partnerships will bring in strategic investors with a vested interest in the future of our Company. This will make 2021 our best year ever – for our shareholders, our customers and our patients.

If you haven't already taken a moment to sign up for our e-mail alerts, be sure to do so by visiting our [website](#). Signing up will ensure that you receive the latest news and announcements when they become available. As always, if you have any additional questions or would like more information, please contact our investor relations' hotline at (877) 895-5647.

Sincerely yours,

Rik J. Deitsch  
Chairman and Chief Executive Officer  
Nutra Pharma Corporation; Stock Symbol: NPHC

*This letter contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). This shareholder letter should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at [www.sec.gov](http://www.sec.gov). Statements made herein are as of the date of this shareholder letter and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.*